DÄ internationalArchive6/2017The Risk of Hypomagnesemia

Correspondence

The Risk of Hypomagnesemia

Dtsch Arztebl Int 2017; 114: 101. DOI: 10.3238/arztebl.2017.0101b

Kraus, A

LNSLNS

Professor Mössner’s article on proton-pump inhibitors (PPI) unfortunately contains no mention of the risk of hypomagnesemia (1). The literature contains a growing number of reports of severe magnesium deficiency caused by PPI intake (2, 3). As a result, in July 2012, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) gave all manufacturers of approved PPI drugs three months to include mention of this risk in their summaries of product characteristics (4). The magnesium status should be borne in mind whenever a patient is taking PPI particularly over the long term or in parallel with other factors that can cause hypomagnesemia, such as diuretic use or diabetes mellitus. Magnesium may need to be given as treatment or as preventive supplementation.

DOI: 10.3238/arztebl.2017.0101b

Dr. med. Anton Kraus

Verla-Pharm Arzneimittel, Tutzing

Anton.Kraus@verla.de

Conflict of interest statement

Dr. Kraus is an employee of Verla-Pharm.

1.
Mössner J: The indications, applications, and risks of proton pump inhibitors—
a review after 25 years. Dtsch Arztebl Int 2016; 113: 477–83 VOLLTEXT
2.
Famularo G, Gasbarrone L, Minisola G: Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 2013; 12: 709–1 CrossRef MEDLINE
3.
Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al.: Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37: 1237–41 CrossRef MEDLINE
4.
Mitteilung des BfArM vom 25.07.2012 www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/textanpassung/TA_ppis_mitteilung.pdf?__blob=publicationFile&v=2) (last accessed on 5th September 2016).
1.Mössner J: The indications, applications, and risks of proton pump inhibitors—
a review after 25 years. Dtsch Arztebl Int 2016; 113: 477–83 VOLLTEXT
2. Famularo G, Gasbarrone L, Minisola G: Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 2013; 12: 709–1 CrossRef MEDLINE
3.Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al.: Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37: 1237–41 CrossRef MEDLINE
4. Mitteilung des BfArM vom 25.07.2012 www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/textanpassung/TA_ppis_mitteilung.pdf?__blob=publicationFile&v=2) (last accessed on 5th September 2016).

Info

Specialities